Open-label, Non-randomised, Single-dose, One Sequence, Two-period, Cross-over Study to Investigate the Effect of Inhibition of P-glycoprotein and Breast Cancer Resistance Protein Transporters by Cyclosporine on the Pharmacokinetics of CHF6001 in Healthy Volunteers
Latest Information Update: 11 Sep 2025
At a glance
- Drugs Tanimilast (Primary)
- Indications Allergic asthma; Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Acronyms DDI2
- Sponsors Chiesi Farmaceutici SpA
Most Recent Events
- 07 Aug 2025 Status changed from recruiting to completed.
- 02 Apr 2025 Planned End Date changed from 13 Oct 2025 to 19 Dec 2025.
- 02 Apr 2025 Planned primary completion date changed from 15 Aug 2025 to 13 Jun 2025.